# **Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### In the Claims:

What is claimed is:

1. (Original) A compound of formula (I):

$$(R)p$$
 $(C)n$ 
 $(R^1)q$ 
 $(I)$ 

wherein:

n is 0,1, or 2;

X is NH, O, or S(O)<sub>m</sub>;

each R is the same or different and is independently selected from the group consisting

of halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,  $-R^{10} \text{cycloalkyl}, \text{ Ay, -NHR}^{10} \text{Ay, Het, -NHHet, -NHR}^{10} \text{Het, -OR}^2, -\text{OAy, -OHet, -R}^{10} \text{OR}^2, -\text{NR}^2 \text{R}^3, -\text{NR}^2 \text{Ay, -R}^{10} \text{NR}^2 \text{R}^3, -\text{R}^{10} \text{NR}^2 \text{Ay, -R}^{10} \text{C(O)R}^2, -\text{C(O)R}^2, -\text{C(O)R}^2, -\text{C(O)NR}^2 \text{R}^3, -\text{C(O)Ay, -C(O)NR}^2 \text{Ay, -C(O)NR}^2 \text{Ay, -C(O)NHR}^{10} \text{Het, -R}^{10} \text{C(O)NR}^2 \text{R}^3, -\text{C(S)NR}^2 \text{R}^3, -\text{R}^{10} \text{C(S)NR}^2 \text{R}^3, -\text{R}^{10} \text{NHC(NH)NR}^2 \text{R}^3, -\text{C(NH)NR}^2 \text{R}^3, -\text{R}^{10} \text{C(NH)NR}^2 \text{R}^3, -\text{S(O)}_2 \text{NR}^2 \text{R}^3, -\text{S(O)}_2 \text{NR}^2, -\text{S(O)}_3 \text{NR}^2, -\text{S(O)}_3$ 

each R<sup>1</sup> is the same or different and is independently selected from the group consisting of halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl, -R<sup>10</sup>cycloalkyl, Ay, -NHR<sup>10</sup>Ay, Het, -NHHet, -NHR<sup>10</sup>Het, -OR<sup>2</sup>, -OAy, -OHet, -R<sup>10</sup>OR<sup>2</sup>, -NR<sup>2</sup>R<sup>3</sup>, -NR<sup>2</sup>Ay, -R<sup>10</sup>NR<sup>2</sup>R<sup>3</sup>, -R<sup>10</sup>NR<sup>2</sup>Ay, -R<sup>10</sup>C(O)R<sup>2</sup>, -C(O)R<sup>2</sup>, -CO<sub>2</sub>R<sup>2</sup>, -R<sup>10</sup>CO<sub>2</sub>R<sup>2</sup>, -C(O)NR<sup>2</sup>R<sup>3</sup>, -C(O)Ay, -C(O)NR<sup>2</sup>Ay, -C(O)Het, -C(O)NHR<sup>10</sup>Het, -R<sup>10</sup>C(O)NR<sup>2</sup>R<sup>3</sup>, -C(S)NR<sup>2</sup>R<sup>3</sup>, -R<sup>10</sup>C(NH)NR<sup>2</sup>R<sup>3</sup>, -R<sup>10</sup>C(NH)NR

 $S(O)_2NR^2R^3$ ,  $-S(O)_2NR^2Ay$ ,  $-R^{10}SO_2NHCOR^2$ ,  $-R^{10}SO_2NR^2R^3$ ,  $-R^{10}SO_2R^2$ ,  $-S(O)_mR^2$ , cyano, nitro, or azido;

each m independently is 0, 1, or 2;

each R<sup>10</sup> is the same or different and is independently selected from alkylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene;

p and q are each independently selected from 0, 1, 2, 3, 4, or 5; each of  $R^2$  and  $R^3$  are the same or different and are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -  $R^{10}$ cycloalkyl, - $R^{10}$ OH, - $R^{10}$ (OR $^{10}$ )<sub>w</sub>, and - $R^{10}$ NR $^4$ R $^5$ ;

w is 1-10;

each of R<sup>4</sup> and R<sup>5</sup> are the same or different and are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl; Ay represents an aryl group;

Het represents a 5- or 6-membered heterocyclyl or heteroaryl group; ring A is aryl or heteroaryl; and pharmaceutically acceptable salts, solvates, and physiologically functional derivatives thereof.

- 2. (Original) The compound of claim 1 wherein X is NH.
- 3. (Original) The compound of claim 1 wherein alkyl is  $C_1$ - $C_6$  alkyl, alkoxy is  $C_1$ - $C_6$  alkoxy, and haloalkyl is  $C_1$ - $C_6$  haloalkyl.
- 4. (Original) The compound of claim 1 wherein at least p or q is not 0.
- 5. (Original) The compound of claim 1 wherein both p and q are each1.
- 6. (Original) The compound of claim 1 wherein n is 1 or 2.
- 7. (Original) The compound of claim 6 wherein n is 1.

#### PR60251USW

- 8. (Original) The compound of claim 1 wherein R is selected from halogen, alkyl, haloalkyl, cycloalkyl, -R<sup>10</sup>cycloalkyl, Ay, Het, -OR<sup>2</sup>, -R<sup>10</sup>OR<sup>2</sup>, -NR<sup>2</sup>R<sup>3</sup>, -COR<sup>2</sup>, -CO<sub>2</sub>R<sup>2</sup>, -CONR<sup>2</sup>R<sup>3</sup>, -S(O)<sub>2</sub>NR<sup>2</sup>R<sup>3</sup>, cyano, nitro, or azido.
- 9. (Original) The compound of claim 8 wherein R is selected from halogen, alkyl, haloalkyl, cycloalkyl, -R<sup>10</sup>cycloalkyl, Ay, Het, -R<sup>10</sup>OR<sup>2</sup>, -NR<sup>2</sup>R<sup>3</sup>, -COR<sup>2</sup>, -CONR<sup>2</sup>R<sup>3</sup>, -S(O)<sub>2</sub>NR<sup>2</sup>R<sup>3</sup>, or cyano.
- 10. (Original) The compound of claim 9 wherein R is selected from halogen, alkyl, or haloalkyl.
- 11. (Original) The compound of claim 10 wherein R is selected from Cl or Br.
- 12. (Currently Ameded) The compound of claim 10 or 11 wherein R is substituted *para* to the depicted N atom.
- 13. (Original) The compound of claim 1 wherein R<sup>1</sup> selected from halogen, alkyl, haloalkyl, Ay, Het, -OR<sup>2</sup>, -R<sup>10</sup>OR<sup>2</sup>, -NR<sup>2</sup>R<sup>3</sup>, -COR<sup>2</sup>, -CO<sub>2</sub>R<sup>2</sup>, -CONR<sup>2</sup>R<sup>3</sup>, -S(O)<sub>2</sub>NR<sup>2</sup>R<sup>3</sup>, -S(O)<sub>m</sub>R<sup>2</sup>, cyano, nitro, or azido.
- 14. (Original) The compound of claim 13 wherein R<sup>1</sup> is selected from halogen, alkyl, haloalkyl, -OR<sup>2</sup>, cyano, or nitro.
- 15. (Original) The compouns of claim 14 wherein R<sup>1</sup> is selected from halogen, alkyl, haloalkyl, -OR<sup>2</sup>.
- 16. (Original) The compound of claim 15 wherein q is 1 or 2.
- 17. (Original) The compound of claim 1 wherein the A ring is aryl.
- 18. (Original) The compound of claim 17 wherein the A ring is phenyl.

- 19. (Original) The compound of claim 1 wherein the A ring is heteroaryl.
- 20. (Original) The compound of claim 19 wherein the heteroaryl is pyrimidinyl, pyridyl, or benzothiazolyl.
- 21. (Original) The compound of claim 20 wherein the heteroaryl is pyrimidinyl or pyridyl.
- 22. (Original) The compound of claim 21 wherein q is 0, 1, or 2.
- 23. (Original) The compound of claim 1 wherein when p is not 0, then each R is the same or different and is independently selected from the group consisting of halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,  $-R^{10}$ cycloalkyl, Ay,  $-NHR^{10}$ Ay, Het, -NHHet,  $-NHR^{10}$ Het,  $-R^{10}$ OR²,  $-NR^2R^3$ ,  $-NR^2Ay$ ,  $-R^{10}NR^2R^3$ ,  $-R^{10}NR^2Ay$ ,  $-R^{10}C(O)R^2$ ,  $-C(O)R^2$ ,  $-CO_2R^2$ ,  $-R^{10}CO_2R^2$ ,  $-C(O)NR^2R^3$ , -C(O)Ay,  $-C(O)NR^2Ay$ , -C(O)Het,  $-C(O)NHR^{10}H$ et,  $-R^{10}C(O)NR^2R^3$ ,  $-C(S)NR^2R^3$ ,  $-R^{10}C(S)NR^2R^3$ ,  $-R^{10}NHC(NH)NR^2R^3$ ,  $-C(NH)NR^2R^3$ ,  $-R^{10}C(NH)NR^2R^3$ ,  $-S(O)_2NR^2R^3$ ,  $-S(O)_2NR^2Ay$ ,  $-R^{10}SO_2NHCOR^2$ ,  $-R^{10}SO_2NR^2R^3$ ,  $-R^{10}SO_2R^2$ ,  $-S(O)_mR^2$ , cyano, nitro, or azido.
- 24. (Original) The compound of claim 1 selected from 6-Bromo-*N*-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Chloro-*N*-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Chloro-*N*-(4-methoxyphenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Chloro-*N*-(4-chlorophenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Chloro-*N*-(4-fluorophenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Chloro-*N*-(4-methylphenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Bromo-*N*-(4-chlorophenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Bromo-*N*-(4-fluorophenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Bromo-*N*-(4-fluorophenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Bromo-*N*-(9-pyrimidin-2-yl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Bromo-*N*-pyrimidin-2-yl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride

- 6-Chloro-N-pyrimidin-2-yl-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Chloro-N-(4,6-dimethoxypyrimidin-2-yl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Chloro-N-(4-methylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Chloro-N-(4,6-dimethylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-pyridin-2-yl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride
- 6-Bromo-N-(5-propylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Methoxy-N-pyrimidin-2-yl-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Methoxy-N-pyrimidin-2-yl-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- *N*-(4,6-Dimethoxypyrimidin-2-yl)-6-methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride
- 6-Bromo-*N*-(4,6-dimethylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride
- 6-Bromo-*N*-[5-(trifluoromethyl)pyrimidin-2-yl]-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Bromo-*N*-[5-(trifluoromethyl)□yridine-2-yl]-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-[(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)amino]nicotinonitrile
- N-(1,3-Benzothiazol-2-yl)-6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- *N*-Pyrimidin-2-yl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 2-Bromo-N-pyrimidin-2-yl-5,6,7,8,9,10-hexahydrocyclohepta[b]indol-6-amine
- 6-Methyl-*N*-pyridin-2-yl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride salt
- Methyl 1-anilino-2,3,4,9-tetrahydro-1*H*-carbazole-6-carboxylate
- 6-[(6-Methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)amino]nicotinonitrile hydrochloride salt
- *N*-Phenyl-6-(trifluoromethyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride
- *N*-Phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Bromo-N-(3-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-(3-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-(1H-indol-5-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-(2-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine

- 6-Bromo-*N*-(2-chlorophenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Bromo-*N*-(2-fluorophenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Bromo-*N*-(3,4-dichlorophenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine; and 6-Bromo-*N*-(4-fluorophenoxy)-2,3,4,9-tetrahydro-1*H*-carbazole.
- 25. (Original) The compound of claim 1 selected from 6-Bromo-*N*-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Chloro-*N*-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Chloro-*N*-(4-methoxyphenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Chloro-*N*-(4-chlorophenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Chloro-*N*-(4-fluorophenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Chloro-N-(4-methylphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-*N*-(4-methoxyphenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Bromo-N-(4-chlorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-*N*-(4-fluorophenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Bromo-*N*-pyrimidin-2-yl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride
- 6-Chloro-N-pyrimidin-2-yl-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Chloro-*N*-(4,6-dimethoxypyrimidin-2-yl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Chloro-N-(4-methylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Chloro-N-(4,6-dimethylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-pyridin-2-yl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride
- 6-Bromo-*N*-(5-propylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- *N*-(4,6-Dimethoxypyrimidin-2-yl)-6-methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride
- 6-Bromo-*N*-(4,6-dimethylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride
- 6-Bromo-*N*-[5-(trifluoromethyl)pyrimidin-2-yl]-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Bromo-*N*-[5-(trifluoromethyl)□yridine-2-yl]-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-[(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)amino]nicotinonitrile *N*-(1,3-Benzothiazol-2-yl)-6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine

2-Bromo-*N*-pyrimidin-2-yl-5,6,7,8,9,10-hexahydrocyclohepta[*b*]indol-6-amine 6-Methyl-*N*-pyridin-2-yl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride salt

Methyl 1-anilino-2,3,4,9-tetrahydro-1*H*-carbazole-6-carboxylate 6-[(6-Methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)amino]nicotinonitrile hydrochloride salt

*N*-Phenyl-6-(trifluoromethyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride

N-Phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine

6-Bromo-N-(3-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine

6-Bromo-N-(3-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine

6-Bromo-N-(2-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine

6-Bromo-N-(2-chlorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine

6-Bromo-N-(2-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine

6-Bromo-N-(3,4-dichlorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine; and

6-Bromo-*N*-(4-fluorophenoxy)-2,3,4,9-tetrahydro-1*H*-carbazole.

26. (Original) The compound of claim 1 wherein the compound of formula (I) further comprises:

$$(R)p$$
 $(C)n$ 
 $(R^1)q$ 
 $(I)$ 

including salts, solvates and pharmaceutically functional derivatives wherein  $R^6$  is H, alkyl,  $-OR^2$ ,  $-NR^2R^3$ , Ay, Het,  $-C(O)R^2$ ,  $-CO_2R^2$ ,  $-CONR^2R^3$ ,  $-S(O)_mR^2$ , or oxo, where  $R^2$  and  $R^3$  are as defined above; and  $R^7$  is H or alkyl, provided that  $R^6$  and  $R^7$  are not both H.

### 27. (Cancelled).

# PR60251USW

28.	(Currently Ameded) A pharmaceutical composition comprising a
comp	oound according to claims 1 to 26, and a pharmaceutically acceptable
carrier.	
29.	(Cancelled).
30.	(Cancelled).
31.	(Cancelled).
32.	(Cancelled).
33.	(Cancelled).
34.	(Cancelled).
35.	(Cancelled).
36.	(Cancelled).
37.	(Cancelled).
38.	(Currently Ameded) A method for the treatment or prophylaxis of
oncogenic viruses, including adenoviruses, retroviruses, and papovavirus	
	y, including polyoma viruses and papilloma viruses comprising the
admi	nistration of a compound according to any one of claims 1 to 26.
	(Currently Ameded) A method for the treatment or prophylaxis of itions or disorders due to HPV infection comprising the administration of a bound according to any one of claims 1 to 26.

## PR60251USW

40. (Original) The method of claim 39 wherein the condition or disorder is warts, genital warts, cervical dysplasia, recurrent respiratory papillomatosis, or cancers associated with papillomavirus infection.